# Accurdx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accurdx

- Industry: Medical Devices & Equipment
- Headquarters: Jinan, China
- Total disclosed funding: $14M
- Latest round: Series A (Sep 1, 2023)
- Investors on record: 3

## About

Based in Jinan, China, and founded in 2017, Shandong Aikeda Biotechnology Co., Ltd., trading as Accurdx, operates as an in vitro diagnostic instrument and supporting reagent manufacturer, focusing on medical diagnostic reagents, and diagnostic instruments. Some affiliations have been established in Beijing, Shanghai, Suzhou, and Hangzhou. Accurdx has obtained 45 production licenses, 10 full-automatic analyzer registrations, 35 reagent registrations, and 83 patents for inventions and other items. In January 2026, Accurdx raised venture funding from new investor Shandong Finance Investment Group.
The products manufactured by the company can be categorized into four categories which are coagulation tests, specific protein tests, genital tract secretion tests, and immune tests. Products within include coagulation analyzers, coagulation reagents, blood sedimentation analyzers, genital secretion analyzers, and dry fluorescence and immune analyzers. The technologies and products can provide clinical laboratory automation solutions for bleeding and bleeding control, cardiovascular disease, and colon cancer screening.
The company generates revenue primarily through the sale of in vitro diagnostic instruments, supporting reagents, and integrated diagnostic systems to clinical laboratories and medical institutions. Additional revenue is derived from the commercialization of automated laboratory solutions and the provision of related technical and support services. Its vertically integrated structure enables coordinated sales of instruments, reagents, and system-level solutions.

## Funding rounds

- Series A, Sep 1, 2023 — Shandong New Growth Drivers Fund Management
- Series A, Sep 26, 2022, $14M — Addor Capital, CITIC Med Fund

## Investors

- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series A
- CITIC Med Fund (https://capitalatlas.ai/funds/citic-med-fund) — Series A
- Shandong New Growth Drivers Fund Management (https://capitalatlas.ai/funds/shandong-new-growth-drivers-fund-management) — Series A